Literature DB >> 34516878

A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering.

Jingen Zhu1, Neeti Ananthaswamy1, Swati Jain1, Himanshu Batra1, Wei-Chun Tang1, Douglass A Lewry2, Michael L Richards2, Sunil A David2, Paul B Kilgore3, Jian Sha3, Aleksandra Drelich3, Chien-Te K Tseng3,4,5, Ashok K Chopra3,4,5, Venigalla B Rao1.   

Abstract

A “universal” platform that can rapidly generate multiplex vaccine candidates is critically needed to control pandemics. Using the severe acute respiratory syndrome coronavirus 2 as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates was engineered by incorporating various viral components into appropriate compartments of phage nanoparticle structure. These include expressible spike genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid proteins in packaged core. Phage decorated with spike trimers was found to be the most potent vaccine candidate in animal models. Without any adjuvant, this vaccine stimulated robust immune responses, both T helper cell 1 (TH1) and TH2 immunoglobulin G subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new nanovaccine design framework might allow the rapid deployment of effective adjuvant-free phage-based vaccines against any emerging pathogen in the future.

Entities:  

Year:  2021        PMID: 34516878      PMCID: PMC8442874          DOI: 10.1126/sciadv.abh1547

Source DB:  PubMed          Journal:  Sci Adv        ISSN: 2375-2548            Impact factor:   14.957


  59 in total

1.  Structure of the three N-terminal immunoglobulin domains of the highly immunogenic outer capsid protein from a T4-like bacteriophage.

Authors:  Andrei Fokine; Mohammad Z Islam; Zhihong Zhang; Valorie D Bowman; Venigalla B Rao; Michael G Rossmann
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Molecular architecture of the prolate head of bacteriophage T4.

Authors:  Andrei Fokine; Paul R Chipman; Petr G Leiman; Vadim V Mesyanzhinov; Venigalla B Rao; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

3.  Promotion of B cell immune responses via an alum-induced myeloid cell population.

Authors:  Michael B Jordan; David M Mills; John Kappler; Philippa Marrack; John C Cambier
Journal:  Science       Date:  2004-06-18       Impact factor: 47.728

Review 4.  SARS-CoV-2 vaccines in development.

Authors:  Florian Krammer
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

5.  Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.

Authors:  Kevin O Saunders; Esther Lee; Robert Parks; David R Martinez; Dapeng Li; Haiyan Chen; Robert J Edwards; Sophie Gobeil; Maggie Barr; Katayoun Mansouri; S Munir Alam; Laura L Sutherland; Fangping Cai; Aja M Sanzone; Madison Berry; Kartik Manne; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Anyway B Kapingidza; Mihai Azoitei; Longping V Tse; Trevor D Scobey; Rachel L Spreng; R Wes Rountree; C Todd DeMarco; Thomas N Denny; Christopher W Woods; Elizabeth W Petzold; Juanjie Tang; Thomas H Oguin; Gregory D Sempowski; Matthew Gagne; Daniel C Douek; Mark A Tomai; Christopher B Fox; Robert Seder; Kevin Wiehe; Drew Weissman; Norbert Pardi; Hana Golding; Surender Khurana; Priyamvada Acharya; Hanne Andersen; Mark G Lewis; Ian N Moore; David C Montefiori; Ralph S Baric; Barton F Haynes
Journal:  Nature       Date:  2021-05-10       Impact factor: 69.504

6.  Structure-based design of prefusion-stabilized SARS-CoV-2 spikes.

Authors:  Ching-Lin Hsieh; Jory A Goldsmith; Jeffrey M Schaub; Andrea M DiVenere; Hung-Che Kuo; Kamyab Javanmardi; Kevin C Le; Daniel Wrapp; Alison G Lee; Yutong Liu; Chia-Wei Chou; Patrick O Byrne; Christy K Hjorth; Nicole V Johnson; John Ludes-Meyers; Annalee W Nguyen; Juyeon Park; Nianshuang Wang; Dzifa Amengor; Jason J Lavinder; Gregory C Ippolito; Jennifer A Maynard; Ilya J Finkelstein; Jason S McLellan
Journal:  Science       Date:  2020-07-23       Impact factor: 47.728

7.  Expression and purification of SARS coronavirus proteins using SUMO-fusions.

Authors:  Xun Zuo; Michael R Mattern; Robin Tan; Shuisen Li; John Hall; David E Sterner; Joshua Shoo; Hiep Tran; Peter Lim; Stefan G Sarafianos; Lubna Kazi; Sonia Navas-Martin; Susan R Weiss; Tauseef R Butt
Journal:  Protein Expr Purif       Date:  2005-02-23       Impact factor: 1.650

8.  A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.

Authors:  Tiong Kit Tan; Pramila Rijal; Rolle Rahikainen; Anthony H Keeble; Lisa Schimanski; Saira Hussain; Ruth Harvey; Jack W P Hayes; Jane C Edwards; Rebecca K McLean; Veronica Martini; Miriam Pedrera; Nazia Thakur; Carina Conceicao; Isabelle Dietrich; Holly Shelton; Anna Ludi; Ginette Wilsden; Clare Browning; Adrian K Zagrajek; Dagmara Bialy; Sushant Bhat; Phoebe Stevenson-Leggett; Philippa Hollinghurst; Matthew Tully; Katy Moffat; Chris Chiu; Ryan Waters; Ashley Gray; Mehreen Azhar; Valerie Mioulet; Joseph Newman; Amin S Asfor; Alison Burman; Sylvia Crossley; John A Hammond; Elma Tchilian; Bryan Charleston; Dalan Bailey; Tobias J Tuthill; Simon P Graham; Helen M E Duyvesteyn; Tomas Malinauskas; Jiandong Huo; Julia A Tree; Karen R Buttigieg; Raymond J Owens; Miles W Carroll; Rodney S Daniels; John W McCauley; David I Stuart; Kuan-Ying A Huang; Mark Howarth; Alain R Townsend
Journal:  Nat Commun       Date:  2021-01-22       Impact factor: 14.919

9.  Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection.

Authors:  Elizabeth M Anderson; Eileen C Goodwin; Anurag Verma; Claudia P Arevalo; Marcus J Bolton; Madison E Weirick; Sigrid Gouma; Christopher M McAllister; Shannon R Christensen; JoEllen Weaver; Philip Hicks; Tomaz B Manzoni; Oluwatosin Oniyide; Holly Ramage; Divij Mathew; Amy E Baxter; Derek A Oldridge; Allison R Greenplate; Jennifer E Wu; Cécile Alanio; Kurt D'Andrea; Oliva Kuthuru; Jeanette Dougherty; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sokratis A Apostolidis; Alex C Huang; Laura A Vella; Leticia Kuri-Cervantes; M Betina Pampena; Michael R Betts; E John Wherry; Nuala J Meyer; Sara Cherry; Paul Bates; Daniel J Rader; Scott E Hensley
Journal:  Cell       Date:  2021-02-09       Impact factor: 41.582

10.  Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.

Authors:  Peter Richmond; Lara Hatchuel; Min Dong; Brenda Ma; Branda Hu; Igor Smolenov; Ping Li; Peng Liang; Htay Htay Han; Joshua Liang; Ralf Clemens
Journal:  Lancet       Date:  2021-01-29       Impact factor: 79.321

View more
  12 in total

1.  A Designer Nanoparticle Platform for Controlled Intracellular Delivery of Bioactive Macromolecules: Inhibition of Ubiquitin-Specific Protease 7 in Breast Cancer Cells.

Authors:  Wynton D McClary; Alexis Catala; Wei Zhang; Fabia Gamboni; Monika Dzieciatkowska; Sachdev S Sidhu; Angelo D'Alessandro; Carlos E Catalano
Journal:  ACS Chem Biol       Date:  2022-07-07       Impact factor: 4.634

2.  Structures of a large prolate virus capsid in unexpanded and expanded states generate insights into the icosahedral virus assembly.

Authors:  Qianglin Fang; Wei-Chun Tang; Andrei Fokine; Marthandan Mahalingam; Qianqian Shao; Michael G Rossmann; Venigalla B Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

Review 3.  What to Expect from COVID-19 and from COVID-19 Vaccine for Expecting or Lactating Women.

Authors:  Roberta Gangi; Angelica Corrias; Roberta Pintus; Maria Antonietta Marcialis; Vassilios Fanos
Journal:  Pediatr Rep       Date:  2022-05-30

Review 4.  CRISPR-Cas systems: role in cellular processes beyond adaptive immunity.

Authors:  Veena Devi; Kusum Harjai; Sanjay Chhibber
Journal:  Folia Microbiol (Praha)       Date:  2022-07-19       Impact factor: 2.629

Review 5.  Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments.

Authors:  Niaz Mahmud; Muzahidul I Anik; M Khalid Hossain; Md Ishak Khan; Shihab Uddin; Md Ashrafuzzaman; Md Mushfiqur Rahaman
Journal:  ACS Appl Bio Mater       Date:  2022-05-18

6.  Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.

Authors:  Mengling Li; Pengju Guo; Cen Chen; Helong Feng; Wanpo Zhang; Changqin Gu; Guoyuan Wen; Venigalla B Rao; Pan Tao
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 8.786

Review 7.  Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy.

Authors:  Amirmasoud Rayati Damavandi; Razieh Dowran; Sarah Al Sharif; Fatah Kashanchi; Reza Jafari
Journal:  Med Microbiol Immunol       Date:  2022-03-02       Impact factor: 4.148

Review 8.  COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.

Authors:  Kuldeep Dhama; Manish Dhawan; Ruchi Tiwari; Talha Bin Emran; Saikat Mitra; Ali A Rabaan; Saad Alhumaid; Zainab Al Alawi; Abbas Al Mutair
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

9.  A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display.

Authors:  Krista G Freeman; Katherine S Wetzel; Yu Zhang; Kira M Zack; Deborah Jacobs-Sera; Sara M Walters; Dominique J Barbeau; Anita K McElroy; John V Williams; Graham F Hatfull
Journal:  Microorganisms       Date:  2021-11-23

10.  Bacteriophage T4 Escapes CRISPR Attack by Minihomology Recombination and Repair.

Authors:  Xiaorong Wu; Jingen Zhu; Pan Tao; Venigalla B Rao
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.